Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a potent modulator of pericellular environment through its proteolytic activity and promotes migration, invasion, and proliferation of tumor cells. During cell migration, MT1-MMP binds to CD44H, a major hyaluronan receptor, through the hemopexin-like (HPX) domain and localizes at the migration front. MT1-MMP is also responsible for shedding CD44H, which supports CD44H-mediated cell migration. In this study, we asked whether the binding of MT1-MMP to CD44H is a prerequisite step for the successive shedding. Deletion of the HPX domain deprived MT1-MMP of its shedding activity. Furthermore, disruption of the CD44H/MT1-MMP complex by overexpressing the HPX fragments resulted in inhibition of the shedding. Thus, the CD44H in the complex appears to be the direct substrate of MT1-MMP for shedding. Interestingly, other members of the MT-MMP family showed varied extents of CD44H shedding. Domain swapping between MT1-MMP and other MT-MMPs revealed that the ability of the HPX domains to bind CD44H is conserved among them. However, the shedding activity was different depending on the catalytic domains. The conserved binding ability of the HPX domains suggests that CD44H may act as a core molecule assembling multiple MT-MMPs on the cell surface.
Introduction
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a member of MMP family and responsible for pericellular proteolysis acting as a potent modulator of cell physiology (Sato et al., 1994; Egeblad and Werb, 2002; Seiki et al., 2003) . Overexpression is frequently associated with malignant tumor . Expression of MT1-MMP in tumor cell lines promotes migration, invasion, and proliferation of cells through its proteolytic activity in the pericellular milieu (Tsunezuka et al., 1996; Ha et al., 2001; Hotary et al., 2003; Seiki et al., 2003; Ueda et al., 2003) . In migrating cells, MT1-MMP mostly localizes at the ruffling membrane areas that form the leading edge of cells Mori et al., 2002) . Such localization of the enzyme is appropriate to act as a 'proteolytic drill' to allow cells to invade the surrounding tissue and matrix. Previously, we reported that CD44 is a critical molecule in this process, directing MT1-MMP to the migratory front (Mori et al., 2002) . CD44 is a cell adhesion molecule and its globular lectin-like domain acts as a binding site for hyaluronan, an abundant glycosaminoglycan that fills intercellular spaces in various tissues. The ligand-binding domain is linked to the plasma membrane through the stem that is followed by the transmembrane and the cytoplasmic domains. While CD44 has many splicing variants that have insertions in the stem region, the basic and most common form is referred to as the hematopoietic type (CD44H). The cytoplasmic domain of CD44 interacts with the actin cytoskeleton and is important for CD44 to localize at the ruffling edge of migrating cells (Naot et al., 1997; Ponta et al., 2003) . MT1-MMP binds to the extracellular portion of CD44H through the hemopexin-like (HPX) domain and colocalizes in the cells.
Coexpression of MT1-MMP and CD44H promotes cell migration accompanied with increased CD44H shedding (Kajita et al., 2001; Vivinus-Nebot et al., 2004) . Shedding of CD44 is an event frequently observed in many types of cells and shed CD44 has been detected in culture supernatants (Goebeler et al., 1996; Kajita et al., 2001; Okamoto et al., 2002; Murai et al., 2003) . Most of the cell lines shed CD44H constitutively. Expression of MT1-MMP generated two new fragments (Nakamura et al., 2004) . In the previous study, we identified the C-terminal sequences of these fragments and the sites were referred to as cleavage site (CS)-1, -2, and -3, respectively from the N-terminus. The cleavage for the constitutive shedding occurs at CS-3 and a disintegrin and metalloproteinase (ADAM)-like proteases were thought to be responsible (Nakamura et al., 2004) . Indeed, ADAM-10 and ADAM-17 were recently identified as enzymes responsible for shedding CD44H in glioblastoma cells (Murai et al., 2003; Nagano et al., 2004) . CS-1 was cleaved by MT1-MMP directly because the same sequence can be cleaved even in recombinant proteins, although CS-2 was not cleaved in the same condition. By using the cleavage site-specific antibodies, CD44H fragments cleaved at CS-1 were detected in human tumors at higher levels compared to the surrounding normal tissues, while those cleaved at CS-3 did not show significant difference (Nakamura et al., 2004) .
Like other members of MMPs, the extracellular portion of MT1-MMP has a catalytic (CAT) domain linked to the HPX domain through hinge region (Massova et al., 1998; Egeblad and Werb, 2002; Seiki et al., 2003) . While the HPX domain is important to associate with CD44H (Mori et al., 2002) , the CAT domain is responsible for the actual shedding activity. We speculate that this shedding is required to keep adhesion of the leading edge at appropriate level. However, it is still not clear whether the shedding of CD44H actually occurs in the complex at the migratory edge. If the CD44H binding via the HPX domain is prerequisite for the following cleavage event, it is most probable that CD44H shedding by MT1-MMP occurs in the complex. The aim of this study was to elucidate how both the CAT and the HPX domains contribute to the CD44H shedding. We also constructed domainswapping chimeras between MT1-MMP and other members of MT-MMPs and carried out comparative studies examining their ability to bind and shed CD44H.
Results
The HPX domain of MT1-MMP is required for binding and shedding CD44H
To confirm the role of the HPX domain of MT1-MMP in binding CD44H, a FLAG-tagged MT1-MMP (MT1-F) and its mutants lacking either the CAT (MT1HPX-F) or the HPX domain (MT1CAT-F) ( Figure 1a ) were constructed and expressed in HT1080 cells that express significant amounts of endogenous CD44H. As shown in Figure 1b , immunoprecipitation of MT1-F coprecipitated highly glycosylated form of endogenous CD44H (95 kDa) (lane 2). MT1HPX-F also precipitated CD44H (lane 4); however, MT1CAT-F did not (lane 3). These results confirm that MT1-MMP binds CD44H through the HPX domain.
Shedding was then examined by expressing CD44H together with MT1-F or its mutants. However, HT1080 cells are not appropriate for this assay because of the large amount of endogenous CD44 shedding, which hampers detection of the newly processed molecules. Therefore, ZR-75-1 cells expressing negligible levels of endogenous CD44H and MT1-MMP were used instead of HT1080 cells. MT1-MMP binds CD44 even in ZR-75-1 cells (data not shown) as reported with other cells including HT1080 (Mori et al., 2002) . In addition, the pattern of the shed CD44 fragments by MT1-MMP in ZR-75-1 cells is almost identical to that of the previously characterized pattern (Nakamura et al., 2004) . Namely, CD44H was expressed as a 95 kDa protein and constitutive shedding of 75 kDa fragment was observed without expression of MT1-MMP ( Figure 1d, lane 2) . This is presumably by the endogenous ADAM-like proteases that cleave CS-3 and generate Fr.3 as reported previously (Figure 1c ) (Nakamura et al., 2004) . Coexpression of MT1-F generated two new species as 37-40 and 50 kDa fragments (referred to as Fr.1 and Fr.2, respectively) accompanied with a dramatic decrease of Fr.3 (lane 3). These fragments correspond to those cleaved at CS-1 and CS-2 (Figure 1c ) (Nakamura et al., 2004) . The phenomenon shiftdown of the molecular weight of CD44H in the cell lysate was similar to that observed in the previous experiments, reflecting a modified glycosylation state induced by MT1-MMP expression (Kajita et al., 2001) . In contrast, MT1CAT-F and MT1HPX-F did not generate Fr.1 or Fr.2 (lanes 4 and 5). In the previous studies, we confirmed that MT1CAT-F is expressed on the cell surface and retained its proteolytic activity Mori et al., 2002) . Thus, the HPX domain is indispensable for MT1-MMP to retain the activity to shed Fr.1 and Fr2.
Competition for CD44H shedding by the HPX domain of MT1-MMP MT1-MMP lacking the HPX domain (MT1CAT-F) failed to shed CD44H. This result may indicate that the HPX domain plays a critical role in CD44H shedding presumably through its ability to bind the substrate. At the same time, it is also possible that the deletion of the HPX domain changed topology of the CAT domain on the cell surface and altered the accessibility of the enzyme to the cleavage sites. Then, we asked whether disruption of the association between MT1-MMP and CD44H by overexpressing the HPX fragments (MT1HPX) results in inhibition of the shedding. Immunoprecipitation of MT1-F again coprecipitated endogenous CD44H as in Figure 2a (lane 2). Coexpression of MT1HPX together with MT1-F reduced CD44H in the precipitates (lanes 3 and 4) presumably causing competition for the binding.
Such competition was also observed in the localization of MT1-F at the ruffling edge together with CD44H. Stimulation of the cells with phorbol 12-myristate 13-acetate (PMA) did not affect the complex formation (data not shown) and further characterized the colocalization of MT1-F and CD44H at the ruffled membrane structure (Figure 2b , upper panel). MT1HPX-F also colocalized with CD44H at the edge (data not shown) as expected by its ability to bind CD44H (Figure 1b) . Coexpression of MT1HPX with MT1-F significantly reduced the FLAG signals colocalized with CD44 at the ruffling edge and increased the scattering dot-like signals that did not overlap with CD44 (lower panel). Figure 2c , lane 3). Coexpression of MT1HPX-F reduced the amount of Fr.1 greatly and increased Fr.3 (lanes 3 and 4). Fr.2 was also reduced slightly by MT1HPX-F in this condition. However, one may argue that overexpression of a membrane protein that binds CD44H prevents accessibility of the shedding enzymes rather in a nonspecific manner. We think this is not the case because expression of MT1HPX did not inhibit the shedding by ADAM-like proteases that generate Fr.3.
CD44H shedding by other MT-MMPs
Since MT-MMPs have similar domain structure in the extracellular portion (the CAT and the HPX domains The expression plasmid for MT1-F, MT1CAT-F, or MT1HPX-F was transfected into HT1080 cells. After 48 h, the cells were lysed and subjected to immunoprecipitation using mouse anti-FLAG M2 mAb as described in Materials and methods. The immunoprecipitated materials (IP) and the whole cell lysates were analysed by Western blotting (WB) using mouse anti-FLAG M2 mAb or rabbit anti-CD44 pAb. (c) Schematic illustration of CD44H. Three cleavage sites (CS1, CS2, and CS3) where the shed fragments (Fr.1, Fr.2, and Fr.3) are generated are indicated with arrows. (d) The expression plasmid for MT1-F, MT1CAT-F, or MT1HPX-F was cotransfected with that for CD44H into ZR-75-1 cells. After 24 h, the culture medium was changed to serum-free medium and cells were cultured for additional 48 h. Then, the conditioned medium (CM) and the cell lysates were collected. These samples were subjected to Western blotting using rabbit anti-CD44 pAb or mouse anti-FLAG M2 mAb MT1HPX was coexpressed with MT1-F in HT1080 cells. The amount of the transfected MT1HPX plasmid was once or twice that of MT1-F. After 48 h, the cells were lysed and subjected to immunoprecipitation using mouse anti-FLAG M2 mAb. The immunoprecipitated materials (IP) and the whole cell lysates were analysed by Western blotting (WB) using mouse anti-FLAG M2 mAb, rabbit anti-CD44 pAb, or mouse anti-MT1HPX mAb. (b) Localization of MT1-MMP and MT1HPX. MT1-F was expressed alone or coexpressed with MT1HPX in HT1080 cells. For coexpression, the amount of the MT1HPX plasmid was twice that of MT1-F. After 48 h, the cells were treated with 100 nM PMA for 1 h and fixed. Immunostaining was performed with mouse anti-FLAG M1 mAb and rat anti-CD44 mAb. The cells were visualized with a goat Alexa 568-conjugated anti-mouse IgG and a goat Alexa 488-conjugated anti-rat IgG. Scale bar, 10 mm. (c) Competition for CD44H shedding by MT1HPX-F. MT1HPX-F was coexpressed with MT1-MMP and CD44H in ZR-75-1 cells. The amount of the MT1HPX-F plasmid was once or twice that of MT1-MMP. The conditioned medium (CM) and the cell lysates were analysed by Western blotting using rabbit anti-CD44 pAb, mouse anti-MT1HPX mAb, or mouse anti-FLAG M2 mAb CD44 shedding by MT-MMP N Suenaga et al linked with a hinge) and are thought to be responsible for pericellular proteolysis (Massova et al., 1998; Egeblad and Werb, 2002; Seiki et al., 2003) , their ability to shed CD44H was also examined (Figure 3 ). MTMMPs were expressed as a FLAG-tagged form like MT1-F and coexpressed with CD44H in ZR-75-1 cells. Expression levels of MT-MMPs varied depending on the enzymes (Cell lysate, Anti-FLAG). Although MT1-, MT2-, MT5-, and MT6-MMP were expressed at comparable levels (lanes 3, 4, 7, and 8), MT3-and MT4-MMP were at low (lanes 5 and 6). MT3-MMP was particularly undetectable because of its potent autodegradation activity and it was detectable only when BB94 was added to the medium (data not shown Figure 4a . Thus, CAT-swapped chimeras and HPXswapped chimeras were constructed. To confirm that the products are expressed on the cell surface, the plasmids encoding these chimeras were transfected into HT1080 cells and the cell surface proteins were labeled with biotin. Then, the cell lysates were prepared and subjected to immunoprecipitation using anti-FLAG M2 monoclonal antibody (mAb). Precipitates were analysed by Western blotting using the same antibody (Figure 4b , Anti-FLAG M2) or HRP-conjugated avidin D (HRP-avidin D). Although two bands (63 and 60 kDa) were detected with anti-FLAG M2 mAb, HRP-avidin D detected only the 60 kDa band. The 60 kDa band corresponds to the active form, as it was detected by anti-FLAG M1 mAb that reacts to FLAG sequence only when it is exposed at the N-terminus (data not shown). Thus, the chimeras are presented on the cell surface mostly as an active form. The amount of the CAT-swapped chimeras on the cell surface appeared to be similar levels (lanes 2-7), although those of the HPX-swapped chimeras appeared to be different (lanes 9-14) . The chimera having the HPX domain of MT4-MMP was different from others, as it was expressed as only a 63 kDa proform and was not detected on the cell surface (lane 12) presumably because of the inappropriate folding and delivery to the surface.
Evaluation of the HPX domains of MT-MMPs
The HPX-swapped chimeras were expressed in HT1080 cells and immunoprecipitated. Then, we examined whether endogenous CD44H is associated with the chimeras by Western blotting (Figure 5a ). CD44H was detected in the precipitate when MT1-F was expressed. The HPX-swapped chimeras precipitated CD44H similarly (lanes 3, 4, 6, and 7). Thus, the HPX domains derived from other MT-MMPs also have the ability to bind CD44H. The exception was the chimera having the HPX domain of MT4-MMP that failed to precipitate CD44H (lane 5). However, it should be noted that it was poorly processed into the active form and was not presented on the cell surface (Figure 4b ). Therefore, it is not clear whether the HPX domain of MT4-MMP surely lacks an ability to bind CD44H.
CD44H and MT1-MMP colocalize at the ruffling edge by their ability to form a complex as reported previously (Mori et al., 2002) . Thus, the chimeras are expected to behave similar to MT1-MMP on the cell surface. To confirm this, immunostaining of the cells was performed using anti-FLAG and anti-CD44 antibodies. Upon stimulation of the cells with PMA, colocalization of both MT1-F and CD44H at the lamellipodia was observed (Figure 2b ). All the HPXswapped chimeras that bound CD44H also colocalized with endogenous CD44H at the lamellipodia (Figure 5b) . Thus, the ability of the HPX domains to bind CD44H appears to be conserved among MT-MMPs.
Then, we tested how the swapped HPX domains in the chimeras affected CD44H shedding by the MT1-MMP-derived CAT domain (Figure 5c ). Although MT1-MMP shed CD44H most efficiently generating Fr.1 and Fr.2, the HPX domains derived from other MT-MMPs also supported the CAT domain of MT1-MMP to shed CD44H (lanes 4, 5, 7, and 8). As expected, the chimera having the HPX domain of MT4-MMP failed to support the shedding (lane 6). 
Evaluation of the CAT domains of MT-MMPs
To evaluate abilities of the CAT domains, the CATswapped chimeras were coexpressed with CD44H. Since all of the chimeras have the HPX domain derived from MT1-MMP, they are expected to bind CD44H similarly and we tested this by expressing the chimeras in HT1080 cells (Figure 6a ). All the chimeras retained the ability to bind CD44H like MT1-F. Then, we examined whether the chimeras could shed CD44H by expressing them in ZR-75-1 cells (Figure 6b ). The CAT domains derived from MT2-and MT3-MMP produced Fr.2, and Fr.1 was almost undetectable if any (lanes 4 and 5). The chimera having the CAT domain from MT5-MMP produced Fr.2 very faintly (lane 7). However, the chimeras having the CAT domains from MT4-and MT6-MMP did not shed CD44H (lanes 6 and 8).
MT1HPX competes with CD44H shedding by the HPX-swapped chimeras
The HPX domains of MT-MMPs have the ability to bind CD44H and they may use conserved interface for the interaction. If this is the case, binding of MT-MMPs to CD44H may compete with each other. Thus, we investigated this possibility by expressing MT1HPX at high levels and monitoring whether the overexpression could inhibit the CD44H shedding caused by the HPXswapped chimeras. All the HPX-swapped chimeras tested shed CD44H again and generated Fr. Expressions of the constructed chimeras were confirmed using HT1080 cells. The expression plasmids for each chimera were transfected. After 48 h, surface biotinylation was performed on these cells. Then, the cells were lysed and subjected to immunoprecipitation using mouse anti-FLAG M2 mAb. The immunoprecipitated materials (IP) were analysed by Western blotting (WB) using mouse anti-FLAG M2 mAb. Biotinylated proteins were detected using HRP-conjugated avidin D. The numbers from 1 to 6 described on the top of the panels represent MT1-F derivatives having the CAT and the HPX domains derived from MT1-, MT2-, MT3-, MT4-, MT5-, and MT6-MMP, respectively interaction between the HPX domains and CD44H, which enables CD44H shedding in the complex, seems to be conserved among MT-MMPs. The HPX fragments derived from MT3-MMP (MT3HPX) also inhibited the CD44H shedding (Fr.1 and Fr.2) by the HPX-swapped chimeras (data not shown).
Discussion
In this study, we demonstrated that the binding of MT1-MMP to CD44H through the HPX domain is crucial for CD44H shedding. The MT1-F mutant in which HPX domain is deleted (MT1CAT-F) lost its ability to bind and shed CD44H in spite of having the CAT domain. Importance of the HPX in CD44H shedding was further demonstrated by the evidence that competition of the interaction between MT1-MMP and CD44H by expressing MT1HPX also inhibited the shedding markedly. The inhibition by MT1HPX was specific to MT1-MMP, because shedding of Fr.3 presumably mediated by ADAM-like proteases was not inhibited. Thus, we concluded that both the CAT and the HPX domains of MT1-MMP play independent and indispensable roles in CD44H shedding. This conclusion suggests that CD44H shedding by MT1-MMP occurs by the following two steps. Firstly, MT1-MMP binds CD44H via the HPX domain and forms a complex. Secondly, the cleavage reaction mediated by the CAT domain follows for shedding. Among MT-MMPs, MT1-MMP showed the most potent activity to shed CD44H and generated Fr.1 and Fr.2. MT2-, MT3-, and MT5-MMP also shed CD44H generating Fr.2, although Fr.1 was hardly detectable. On the other hand, MT4-and MT6-MMP did not shed CD44H. The CAT-swapped chimeras also followed the results. Thus, the CD44H shedding by MT-MMPs appears to depend largely on the ability of CAT domain of each MT-MMP.
On the other hand, the HPX-swapped chimeras demonstrated that the HPX domains of MT-MMPs have the ability to bind CD44H, although that of MT4-MMP is not clear. The mode of interaction between the HPX domains and CD44H appears to be conserved at least in the MT-MMP group, because the HPX domain of MT1-MMP (MT1HPX) and MT3-MMP (MT3HPX) can compete the CD44H shedding by the HPX-swapped chimeras.
The conserved ability of the HPX domains to bind CD44H raised the possibility that CD44 plays a central role in assembling different MMPs on the cell surface. Since CD44 localizes at the leading edge of migrating cells, it may act as a core molecule to form invasion machinery including MMPs at the front. In addition to MT-MMPs, MMP-9 is reported to bind CD44 (Bourguignon et al., 1998; Abecassis et al., 2003; Yu and Stamenkovic, 1999) and activates latent form of transforming growth factor b (TGF-b) (Yu and Stamenkovic, 2000) . Although the domain of MMP-9 responsible for the binding is not clear, it may use a (Massova et al., 1998; Egeblad and Werb, 2002) . The binding is mediated by its affinity to heparan sulfate proteoglycan, which modifies the v3 region of a variant form of CD44 (Yu et al., 2002) . Thus, one of the functions of CD44, an enigmatic multifunctional protein, may be to act as a core protein to assemble a variety of cell surface proteins depending on the cellular functions such as migration and invasion.
Although MT-MMPs were demonstrated to bind CD44 while some shed CD44, this does not necessarily mean that MT-MMPs are the major proteases for CD44 shedding. Indeed, ADAM-10 (Murai et al., 2003; Nagano et al., 2004) and ADAM-17 (Nagano et al., 2004) were also identified as proteases responsible for shedding. In a previous study, we demonstrated that MT1-MMP and ADAM-like proteases cleave different sites and established a sandwich EIA system to quantify each shed fragment generating neo-epitope antibodies (Nakamura et al., 2004) . In oral carcinomas, the amount of CD44 fragments cleaved at MT1-MMP sites was measured and was found to be significantly increased as were those at the ADAM site compared to the amount in normal tissue. The relative amount of fragments shed at the ADAM site was 4-5-fold the amount of those at the MT1-MMP sites (Nakamura et al., 2004) .
In conclusion, we demonstrated that both the CAT and the HPX domains of MT-MMPs are essential to shed CD44H. Based on this result, we propose that CD44H may act as a core molecule to assemble MTMMPs at the leading edge of migrating cells. Thus, disrupting interaction between MT-MMPs and CD44 may provide a clue to develop new strategies to inhibit invasion of malignant tumors.
Materials and methods

Cell culture and transfection
The human fibrosarcoma cell line HT1080 cells were maintained in Dulbecco's modified Eagle's medium (Sigma) containing 10% fetal bovine serum (FBS; Life Technologies) and penicillin/streptomycin, and the human breast carcinoma cell line ZR-75-1 cells in RPMI 1640 medium (Sigma) containing 10% FBS and kanamycin in a humidified 371C incubator. The cells were seeded in six-well plates at 1.5 Â 10 5 cells/well and cultured for 16 h before transfection. Expression plasmids were transfected using FuGENE6t (Roche Molecular Biochemicals) according to the manufacturer's instructions.
Construction of MT1-MMP mutants and chimeras
FLAG epitope-tagged MT-MMP expression constructs (MT1-F, MT2-F, MT3-F, MT4-F, MT5-F, and MT6-F) were generated as described previously (Kojima et al., 2000; Itoh et al., 2001; Kajita et al., 2001) . The mutants in which HPX domains (Ile318-Gly535) were deleted (MT1CAT, MT1CAT-F with a FLAG epitope-tagged) and CAT domains (Tyr112-Pro312) were deleted (MT1HPX, MT1HPX-F/-M with either a FLAG or a c-Myc epitope-tagged) were also generated in the same way (Itoh et al., 1999) . Chimeric MT1-F mutants in which the CAT domain of MT1-MMP (Tyr112-Gly284) was exchanged with those ones derived from MT2-, MT3-, MT4-, MT5, and MT6-MMP (Tyr132-Gly304, Tyr120-Gly291, Gln129-Gly298, Tyr156-Gly327, and Tyr108-Gly280, respectively) and in which the HPX domain of MT1-MMP (Cys319-Cys508) was exchanged with those derived from MT2-, MT3-, MT4-, MT5, and MT6-MMP (Cys370-Cys559, Cys343-Cys532, Cys335-Cys526, Cys380-Cys569, and Cys317-Cys508, respectively) were generated using overlapping primers designed for recombining each domain as illustrated in Figure 4a by the polymerase chain reaction (PCR) extension method of Ho et al. (1989) . The cDNA encoding CD44H was obtained by reverse transcription-PCR as described previously (Kajita et al., 2001) . These constructs were cloned into pSG5 expression vector (Stratagene).
Antibodies and inhibitors
Rabbit polyclonal antibody (pAb) was prepared using the stem region of human CD44H. Mouse anti-MT1-MMP mAb recognizing the HPX domain (222-1D8) was a gift of Dr Iwata (Daiichi Fine Chemical Co. Ltd, Takaoka, Japan). We also used commercially available antibodies as follows: a mouse anti-FLAG epitope M1/M2 mAb from Sigma, a mouse anti-c-Myc epitope mAb from Roche Molecular Biochemicals, a sheep peroxidase-conjugated anti-mouse IgG and a donkey peroxidase-conjugated anti-rabbit IgG from Amersham Biosciences KK, a rat anti-CD44 mAb from Chemicon, and a goat Alexa 568-conjugated anti-mouse IgG and a goat Alexa 488-conjugated anti-rat IgG from Molecular Probes.
BB94 was a gift of Dr Peter D Brown (British Biotech Pharmaceuticals Ltd, Oxford, UK).
Immunoprecipitation
After transfection, cells were cultured for 48 h. Then, cells were solubilized in the lysis buffer (1% CHAPS, 25 mM HEPESNaOH (pH7.5), 150 mM NaCl, Protease Inhibitor Cocktail Set I (Calbiochem)) at 41C for 1 h. Cell lysates were clarified by centrifugation at 15 000 r.p.m. for 20 min, and the supernatant was collected and incubated with anti-FLAG M2 mAbconjugated agarose beads (Sigma) at 41C for 12 h. The beads were washed with the lysis buffer four times, and the materials bound to the beads were eluted with the lysis buffer containing 200 mg/ml FLAG peptide. The samples were then subjected to Western blot analysis.
Western blot analysis
To detect proteins in the culture supernatant, the medium was treated with 10% trichloroacetic acid. Immunoprecipitated materials (IP), cell lysates, and trichloroacetic acid-precipitated proteins were separated by SDS-PAGE, and proteins in the gel were transferred to a polyvinylidene difluoride membrane. After blocking the membrane with 5% fat-free dry milk in phosphate-buffered saline (PBS), the membrane was probed with a primary antibody specific to each protein. Proteins were visualized using a peroxidase-conjugated secondary antibody.
Cell surface biotinylation
At 48 h after transfection, the cells were incubated with 0.1 mg/ml. EZ-Linkt Sulfo-NHS-LC-Biotin (Pierce) in PBS containing 0.9 mM CaCl 2 and 0.5 mM MgCl 2 (PBS( þ )) at 41C for 30 min and the reaction was stopped by washing cells with PBS( þ ) three times. Then, cells were collected as described in Immunoprecipitation. The immunoprecipitated materials were subjected to Western blot analysis, and biotinylated proteins were visualized using a peroxidase-conjugated avidin D (Vector).
Immunofluorescence staining
Transfected cells were cultured on glass coverslips for 16 h, and cells were treated with 100 nM PMA (Sigma) for 1 h and then fixed with 3% paraformaldehyde in Tris-bufferd saline (TBS). After blocking with 5% goat serum and 3% bovine serum albumin in TBS, the cells were reacted with a mouse anti-FLAG M1 mAb and a rat anti-CD44 mAb. A goat Alexa 568 conjugated anti-mouse IgG and a goat Alexa 488-conjugated anti-rat IgG were used as secondary antibodies. The signals were analysed using a confocal laser microscope (Bio-Rad).
Abbreviations ADAM, a disintegrin and metalloproteinase; MT-MMP, membrane-type matrix metalloproteinase; PMA, phorbol 12-myristate 13-acetate.
